<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01522625</url>
  </required_header>
  <id_info>
    <org_study_id>EMRP36100N</org_study_id>
    <nct_id>NCT01522625</nct_id>
  </id_info>
  <brief_title>Tenofovir in Chronic Hepatitis B With Mild ALT Elevation</brief_title>
  <official_title>Efficacy of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients With High Viral Load But Slight Aminotransferase Elevation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>E-DA Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taipei Institute of Pathology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>E-DA Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to clarify whether patients with chronic hepatitis B with high viral load
      will benefit from oral antiviral therapy despite only mildly elevated serum liver enzyme.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic hepatitis B (CHB) is a serious disease in Taiwan, leading to substantial morbidity
      and mortality including hepatic failure, liver cirrhosis, and hepatocellular carcinoma (HCC).
      Recently a large body of evidence supports that high level of serum HBV DNA is an independent
      risk factor for late complications in CHB patients. Nucleos(t)ide analogues (NUC) are
      effective antiviral therapy that can potently inhibit replication of hepatitis B virus (HBV),
      and has been widely used in management of patients with CHB. Current practice guidelines
      recommend using serum alanine aminotransferase (ALT) &gt; 2 times of the upper limit of normal
      (ULN) as the prerequisite to initiate antiviral therapy in compensated CHB patients without
      liver cirrhosis. However, serum ALT level does not exactly correlate with serum HBV DNA or
      liver tissue injury. Whether antiviral therapy improves outcomes of patients with slightly
      elevated ALT (i.e. 1-2 folds of ULN) remains unknown.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of hepatic necroinflammation and fibrosis</measure>
    <time_frame>Within one month after completion of antiviral therapy</time_frame>
    <description>Primary outcome is the severity of necroinflammation and fibrosis in liver tissue as evaluated by Knodell and Ishak scoring system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Undetectable hepatitis B viral DNA</measure>
    <time_frame>Within one month after completion of antiviral therapy</time_frame>
    <description>HBV DNA viral DNA not detected in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalization of serum alanine aminotransferase</measure>
    <time_frame>Within one month after completion of antiviral therapy</time_frame>
    <description>serum ALT &lt;40 IU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum level of HBsAg</measure>
    <time_frame>Within one month after completion of antiviral therapy</time_frame>
    <description>quantification of serum HBV serface antigen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse reaction</measure>
    <time_frame>Within one month after completion of antiviral therapy</time_frame>
    <description>Defined as death, life threatening event, permanent or temporary disability, and hospitalization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>TDF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tenofovir disoproxil fumarate (TDF) 300mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tenofovir disoproxil fumarate 300mg per day</intervention_name>
    <description>tenofovir disoproxil fumarate 300mg per day for 3 years</description>
    <arm_group_label>TDF</arm_group_label>
    <other_name>Viread® (Gilead Sciences Inc)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, identical to TDF in appearance, once daily for 3years</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 25 to 70 years,

          -  serum HBsAg positivity for more than 6 months,

          -  positive or negative serum HBeAg,

          -  serum HBV DNA more than 2,000 IU/mL,

          -  highest serum ALT &gt; 1 fold of ULN, but &lt; 2 X ULN on at least two occasions (≧ 3 months
             apart) in the preceding one year,

        Exclusion Criteria:

          -  co-infection with HIV, HCV, or HDV,

          -  previous exposure to HBV antiviral therapy for more than 12 weeks,

          -  presence of cirrhosis on histopathology,

          -  hepatic decompensation defined as serum bilirubin &gt; 2mg/dl and prolonged prothrombin
             time &gt; 3 seconds,

          -  concurrent malignant diseases including hepatocellular carcinoma,

          -  severe co-morbidity with life expectancy &lt; 1year,

          -  pregnant or lactating women,

          -  organ transplantation except cornea or hair transplant,

          -  suspected or confirmed chronic liver diseases from etiologies other than HBV (e.g.
             alcoholic hepatitis, Wilson disease, Hemochromatosis…etc),

          -  serum creatinine &gt;1.5mg/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yao-Chun Hsu, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>E-Da Hospital, Kaohsiung, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jaw-Town Lin, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>National Taiwan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chia-Yi Christine Hospital</name>
      <address>
        <city>Chia-Yi</city>
        <zip>539</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>E-Da Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>824</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi Mei Medical Center, Liouying</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hosp</name>
      <address>
        <city>Taipei</city>
        <zip>104</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital Yun-Lin Branch</name>
      <address>
        <city>Yunlin County</city>
        <zip>640</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2012</study_first_submitted>
  <study_first_submitted_qc>January 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2012</study_first_posted>
  <last_update_submitted>March 20, 2017</last_update_submitted>
  <last_update_submitted_qc>March 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>E-DA Hospital</investigator_affiliation>
    <investigator_full_name>Tu, Yuan-Kun</investigator_full_name>
    <investigator_title>superintendent</investigator_title>
  </responsible_party>
  <keyword>chronic hepatitis B</keyword>
  <keyword>hepatitis B viral DNA</keyword>
  <keyword>antiviral therapy</keyword>
  <keyword>Tenofovir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

